Fusion-Based Biomarkers
                            for Targeted Therapy

                            We have integrated DNA and RNA sequencing results
                            for detection of fusion genes with higher sensitivity.

                            DNA+RNA-based analysis
                            of Fusion

                            RNA sequencing is a supplement to fusion detection

                            In Chinese solid tumor cohort, 60.2% of fusion could
                            be identified both in DNA&RNA, 21.4% of fusion was
                            DNA only and 18.4% was RNA only.

                            Gene fusions

                            Overview of gene rearrangement in Chinese
                            cohort including kinase gene fusions and LOF
                            rearrangement of tumor suppressor genes.
                            Different driver genes and their partners were
                            identified in the cohort. The thickness of the line
                            indicated the number of cases with relative gene

                            NTRK family gene fusions

                            Among 5,388 clinical cases, 22 (0.4%) patients
                            were found harboring NTRK1/3 fusions by
                            next-generation sequencing testing, which was
                            further confirmed by pan-Trk IHC or PCR.
                            NTRK fusions were detected more in fibrosarcoma
                            and colorectal cancer at a ratio of 11.1% and 1.1%,

                            FGFR family gene fusions

                            From over 4,000 solid tumor patients, 6.6% had FGFR 1-4 variations. The incidences of genomic
                            alterations on FGFR1, 2, 3, and 4 were 2.8%, 1.6%, 1.2% and 1%, respectively. Amplification was the
                            most common variation type of FGFR, which accounted for 47% of all the genomic alterations, followed
                            by mutations (41.5%) and fusions (11.4%).

                            Targeted Therapy


                            The 5000+ Chinese solid tumor patients
                            included 58.3% males and 41.7% females.
                            Among patients with BRCA1/2 mutations,74.7%
                            patients harbored somatic mutations. 24.3%
                            patients harbored germline mutations and 1.0%
                            patients harbored both somatic and germline


                            Distriution and frequency of ERBB2 variants in
                            5000+ Chinese solid tumor patients.


                            We have leveraged multiple techniques (DNA, RNA, IHC, etc.) to help identify
                            immunotherapy-related biomarkers for our patients.


                            The landscape of tumor mutational burden(TMB)
                            in 10,000+ Chinese solid tumor patients.


                            The landscape of PD-L1 expression on varoius
                            types of tumor cells in 3,000+Chinese solid
                            tumor patients.